Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Adalimumab Biosimilar Launched for 1/5 Humira Price (in India)
Transcript
Adalimumab Biosimilar Launched for 1/5 Humira Price (in India) Published on Rheumatology Network (http://www.rheumatologynetwork.com) Adalimumab Biosimilar Launched for 1/5 Humira Price (in India) News [1] | December 10, 2014 | Rheumatoid Arthritis [2], Psoriatic Arthritis [3], Spondyloarthritis [4] By Lois Wingerson [5] The firm Cadila is launching its biosimilar Exemptia in India for about 1/5 the price tag of Abbot's Humira. Most biosimilars to date are sold at roughly two-thirds the cost of the FDA-approved versions. Source: Rheumatology Network According to a report from Reuters, the Indian pharmaceutical firm Cadila Healthcare Ltd. has launched a biosimilar version of adalimumab that will sell for 20% of the cost paid for Abbott's Humira in the United States. The disappointingly high cost of many biosimilars compared to the already-approved drugs was a frequent topic of discussion at the recent annual meeting of the American College of Rheumatology in Boston. Prices of biosimilars to date are said to hover around 70% of the cost of the original drug. According to a recent study published in Clinical Economics and Outcomes Research, based on Medicaid claims, the annual cost of treatment with Humira is $20,983. Cadila has launched its biosimilar in India under the name Exemptia. Reportedly the company has scheduled talks with regulators in the US. Source URL: http://www.rheumatologynetwork.com/rheumatoid-arthritis/adalimumab-biosimilar-launched-15-hum ira-price-india Links: [1] http://www.rheumatologynetwork.com/news [2] http://www.rheumatologynetwork.com/rheumatoid-arthritis [3] http://www.rheumatologynetwork.com/psoriatic-arthritis [4] http://www.rheumatologynetwork.com/spondyloarthritis [5] http://www.rheumatologynetwork.com/authors/lois-wingerson Page 1 of 1
